What's in Xiao-Ming Mao's pipeline?

Xiao-Ming Mao has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Xiao-Ming Mao's portfolio?

Top competitors by shared drug class: Newron Pharmaceuticals SPA.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/xiao-ming-mao.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Xiao-Ming Mao — Portfolio Competitive Intelligence Brief

Xiao-Ming Mao pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
MMI combined with IID	MMI combined with IID	marketed
MMI	MMI	marketed	MAO-B inhibitor	MAO-B	Neurology

Therapeutic area mix

Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Newron Pharmaceuticals SPA · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Xiao-Ming Mao:

Cite this brief

Drug Landscape (2026). Xiao-Ming Mao — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/xiao-ming-mao. Accessed 2026-05-16.